Esperion Therapeutics, Inc.ESPRNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Year-over-year net income growth rate
Latest
-146.23%
↓ 3956% below average
Average (39q)
-3.61%
Historical baseline
Range
High:259.25%
Low:-201.48%
CAGR
+11.0%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -146.23% |
| Q2 2025 | 68.55% |
| Q1 2025 | -89.77% |
| Q4 2024 | 27.79% |
| Q3 2024 | 52.32% |
| Q2 2024 | -201.48% |
| Q1 2024 | 208.30% |
| Q4 2023 | -36.59% |
| Q3 2023 | 17.39% |
| Q2 2023 | 19.09% |
| Q1 2023 | -11.23% |
| Q4 2022 | -0.67% |
| Q3 2022 | 16.90% |
| Q2 2022 | -16.91% |
| Q1 2022 | 12.88% |
| Q4 2021 | 6.15% |
| Q3 2021 | -58.89% |
| Q2 2021 | 51.98% |
| Q1 2021 | 12.96% |
| Q4 2020 | -22.28% |
| Q3 2020 | -168.56% |
| Q2 2020 | 259.25% |
| Q1 2020 | -26.32% |
| Q4 2019 | 9.41% |
| Q3 2019 | -26.11% |
| Q2 2019 | -162.05% |
| Q1 2019 | 245.54% |
| Q4 2018 | -20.29% |
| Q3 2018 | -9.14% |
| Q2 2018 | 0.87% |
| Q1 2018 | -21.74% |
| Q4 2017 | 16.21% |
| Q3 2017 | -4.34% |
| Q2 2017 | -6.90% |
| Q1 2017 | -40.01% |
| Q4 2016 | -66.39% |
| Q3 2016 | -23.99% |
| Q2 2016 | 3.77% |
| Q1 2016 | -11.15% |
| Q4 2015 | -2.51% |